The Practice and Thinking of Pharmacovigilance at the Municipal Level under COVID-19

doi:10.19803/j.1672-8629.2020.10.08

Abstract

Abstract: Objective To summarize the practice of pharmacovigilance in Shenzhen during the outbreak of COVID-19, and to consider the construction of pharmacovigilance system. Methods On the basis of pharmacovigilance practice in Shenzhen, literature research was conducted to analyze the theoretical connotation and system composition of pharmacovigilance. Results The development of pharmacovigilance work under public health emergencies required the establishment of a more complete risk monitoring, data sharing, and utilization mechanism. Conclusion It is necessary to incorporate the construction of the pharmacovigilance system into the overall public health technology system plan from a national perspective, and to improve the capacity of drug risk monitoring and emergency response in terms of expanding data sources, strengthening information construction, building a data sharing mechanism, and formulating effective emergency response plans.

Key words: COVID-1P, emergencies in public health, pharmacovigilance, practices

CLC Number:

R951

WU Wenyu, XIAO Xiao, WU Jianru. The Practice and Thinking of Pharmacovigilance at the Municipal Level under COVID-19[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 688-691.

References

[1] Wang LH.Characteristics and countermeasures of 2019-nCoV infection[J]. Chinese Journal of Experimental and Clinial Infectious Diseases(中华实验和临床感染病杂志(电子版)), 2020, 14(1): 1-5.
[2] Bian Y, Yang ZY, Xiong Y, et al.Discussion on clinical pharmaceutical service model in prevention and treatment of corona virus disease 2019[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2020, 39(4): 212-217.
[3] Song Y, Yang Y.Establishment and Operation of EU Pharmacovigilance System and Its Implementation Progress[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(7): 401-406.
[4] Song L, Zhang BK.Pharmacovigilance Systems in Europe and US and Its Impl ication for China[J]. China Pharmacy(中国药房), 2009, 20(14):1043-1045.
[5] Bihan K, Lebrun-Vignes B, Funck-Brentano C, et al.Uses of pharmacovigilance databases: An overview[EB/OL].(2020-02-26) [2020-04-23].https://doi.org/10.1016/j.therap.2020.02.022.
[6] Begaud B.Pharmacovigilance in France: a decentralized approach// Strom BL, Velo G. Drug epidemiology and post-marketing surv- eillance[M]. New York: Pleunm Press, 1992.
[7] Cai W, Ji DX, Zhao X.The Distinction of Pharmacovigilance with Adverse Drug Reaction Monitoring[J]. International Medicine and Health Guidance News(国际医药卫生导报), 2006, 12(20):48-50.
[8] Su C, Qiu JX.Introduction and inspiration of pharmacovigilance additional monitoring in European Union[J]. Drug Evaluation Research(药物评价研究), 2014, 37(1):7-10.
[9] Wu T, Chu WG, Liu ZY.The study on the construction and operation of strategic national stockpile of USA[J]. Chinese Pharmaceutical Affairs(中国药事), 2009, 23(12):1230-1233.
[10] Du WM, Zhang JH, Wang LX.The importance of pharmacovigilance- drug safety monitoring (2)[J]. Drug Evaluation(药品评价), 2004, 1(2):106-114.
[11] Liu W, Chen YX.Adverse Drug Reaction Monitoring and Pharmacovigilance[J]. China Licensed Pharmacist(中国执业药师), 2008, 5(8):18-20.
[12] Hu JL, Xu ZM, Luo ZY. Construction of emergency medicine guarantee system for public health emergencies[J]. Hospital Adm- inistration Journal of Chinese People's Liberation Army(解放军医院管理杂志), 2013, 20(8):722, 742.
[13] Li YR, Cui YM, Wang HX, et al.Enlightenment of American medical countermeasures policies on the drug evaluation, approval and management in response to public health emergencies in China[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2020, 36(7):907-911.
[14] Sun Y.Considerations on drug review and approval policies related to public health emergencies[J]. Drug Evaluation Research(药物评价研究), 2020, 43(3):402-411.
[15] Xu DQ, Xu XJ, Wang J.Practice and Thinking of Drug Emergency Support for Sudden Public Health Events[J]. Chinese Journal of Medical Guide(中国医药导刊), 2009, 11(12):2166-2167.
[16] Wang CG, Wang DF, Xu LL, et al.Investigation and reflection onf the demand of public reporting of adverse drug reaction in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(7): 402-406.
[17] Hou YF, Wang L, Dong D, et al.Research of Data Mining in Monitoring Risk of Vaccines[J]. Chinese Pharmaceutical Affairs(中国药事), 2011, 25(5):434-437.
[18] Berbain T, Pariente A, Miremont-Salamé G, et al.Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database[J]. Drug Safety, 2020, 43(3): 243-253.
[19] Wang L.Opportunities and Challenges in Using Medical Big Data to Monitor and Evaluate Drug Safety[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(11):660-664.
[20] Xu YM, Li XL, Wang L, et al.Exploration of the connection between hospital information system and national adverse drug reaction monitoring system[J]. Chinese Journal of Medical Guide(中国医药导刊), 2017, 19(3):317-318.
[21] Tan ZX, Wu ST, Han XP.References and enlightenments from the public health emergency response systems of the United States of America and Japan-Pneumonia epidemic response to novel coronavirus pneumonia in China[J]. Health Economics Research(卫生经济研究), 2020, 37(3) :11-16.
[22] Tang R, Liu ZX.Emergent medicine supply in momentous public emergency events[J]. Herald of Medicine(医药导报), 2009, 28(4): 407-410.
[23] Jiang T, Liao YB, He SZ, et al.Analysis of literacy on safe drug use and its influencing factors among residents of Yuexiu district, Guangzhou[J]. Chinese Journal of Health Education(中国健康教育), 2013, 29(10):923-926.
[24] Wang T, Wang D, Dong D.Thoughts on Constructing Chinese Pharmacovigilance System[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2019(1):37-41.